BioStock: SynAct Pharma raises 60,5 MSEK through a directed share issue

Biotech company SynAct Pharma has decided to carry out a directed share issue of approximately 60,5 Mkr to an entity managed by Heights Capital Management. The funding enables the continued development of their primary drug candidate resomelagon. The capital will also be used for business development activites. 

Read the full article at biostock.se:

https://www.biostock.se/en/2023/10/synact-pharma-raises-605-msek-through-a-directed-share-issue/

This is a press release from BioStock - Connecting Innovation & Capital. https://www.biostock.se